Capuramycin

Details

• Internal ID: 133291b0-2dc7-4ea3-95ad-73d0eaeb02a5
• Taxonomy: Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > N-acyl-alpha amino acids and derivatives
• IUPAC Name: (2S,3S,4S)-2-[(1R)-2-amino-1-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-3-methoxyoxolan-2-yl]-2-oxoethoxy]-3,4-dihydroxy-N-[(3S)-2-oxoazepan-3-yl]-3,4-dihydro-2H-pyran-6-carboxamide
• InChI: InChI=1S/C23H31N5O12/c1-37-15-14(32)21(28-7-5-12(30)27-23(28)36)39-16(15)17(18(24)33)40-22-13(31)10(29)8-11(38-22)20(35)26-9-4-2-3-6-25-19(9)34/h5,7-10,13-17,21-22,29,31-32H,2-4,6H2,1H3,(H2,24,33)(H,25,34)(H,26,35)(H,27,30,36)/t9-,10-,13-,14+,15-,16-,17+,21+,22+/m0/s1
• InChI Key: BISOEENGZHMDEO-RLXIHFJVSA-N
• Popularity: 36 references in papers

Physical and Chemical Properties

• Molecular Formula: C₂₃H₃₁N₅O₁₂
• Molecular Weight: 569.50 g/mol
• Exact Mass: 569.19692144 g/mol
• Topological Polar Surface Area (TPSA): 248.00 Ų
• XlogP: -4.10
• Atomic LogP (AlogP): -4.57
• H-Bond Acceptor: 13
• H-Bond Donor: 7
• Rotatable Bonds: 8

Synonyms

• 102770-00-3
• Antibiotic 446S3-1
• CHEMBL96695
• 624X0OXY6Y
• (2S,3S,4S)-2-[(1R)-2-amino-1-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-3-methoxyoxolan-2-yl]-2-oxoethoxy]-3,4-dihydroxy-N-[(3S)-2-oxoazepan-3-yl]-3,4-dihydro-2H-pyran-6-carboxamide
• A-500359 B
• (2~{S},3~{S},4~{S})-2-[(1~{R})-2-azanyl-1-[(2~{S},3~{S},4~{R},5~{R})-5-[2,4-bis(oxidanylidene)pyrimidin-1-yl]-3-methoxy-4-oxidanyl-oxolan-2-yl]-2-oxidanylidene-ethoxy]-3,4-bis(oxidanyl)-~{N}-[(3~{S})-2-oxidanylideneazepan-3-yl]-3,4-dihydro-2~{H}-pyran-6-carboxamide
• BRN 5210055
• 446S3-1
• UNII-624X0OXY6Y
• SCHEMBL14598937
• DTXSID501318180
• BDBM50135599
• beta-D-Allofuranuronamide, 1-deoxy-5-O-(4-deoxy-N-(hexahydro-2-oxo-1H-azepin-3-yl)-beta-L-erythro-hex-4-enopyranuronamidosyl)-1-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-O-methyl-, (S)-
• A-500359B
• (2S,3S,4S)-2-((R)-2-Amino-1-((2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl)-2-oxoethoxy)-3,4-dihydroxy-N-((S)-2-oxoazepan-3-yl)-3,4-dihydro-2H-pyran-6-carboxamide
• (2S,3S,4S)-2-[(1R)-2-amino-1-[(2S,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-hydroxy-3-methoxy-tetrahydrofuran-2-yl]-2-oxo-ethoxy]-3,4-dihydroxy-N-[(3S)-2-oxoazepan-3-yl]-3,4-dihydro-2H-pyran-6-carboxamide
• (2S,3S,4S)-2-{(1R)-2-amino-1-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-3-methoxytetrahydrofuran-2-yl]-2-oxoethoxy}-3,4-dihydroxy-N-[(3S)-2-oxoazepan-3-yl]-3,4-dihydro-2H-pyran-6-carboxamide (non-preferred name)
• (4S,5S,6S)-6-{(R)-Carbamoyl-[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-hydroxy-3-methoxy-tetrahydro-furan-2-yl]-methoxy}-4,5-dihydroxy-5,6-dihydro-4H-pyran-2-carboxylic acid ((S)-2-oxo-azepan-3-yl)-amide
• (6-{(1R)[(2S,3S,4R,5R)-5-(2,4-Dioxo(1,3-dihydropyrimidinyl))-4-hydroxy-3-methoxyoxolan-2-yl]carbamoylmethoxy}(4S,5S,6S)-4,5-dihydroxy(4H-5,6-dihydropyran-2-yl))-N-((3S)-2-oxoazaperhydroepin-3-yl)carboxamide
• .ALPHA.-L-TALOFURANURONAMIDE, 1-DEOXY-5-O-(4-DEOXY-N-((3S)-HEXAHYDRO-2-OXO-1H-AZEPIN-3-YL)-.BETA.-L-ERYTHRO-HEX-4-ENOPYRANURONAMIDOSYL)-1-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-3-O-METHYL-
• .ALPHA.-L-TALOFURANURONAMIDE, 1-DEOXY-5-O-(4-DEOXY-N-(HEXAHYDRO-2-OXO-1H-AZEPIN-3-YL)-.BETA.-L-ERYTHRO-HEX-4-ENOPYRANURONAMIDOSYL)-1-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-3-O-METHYL-, (S)-
• 1-DEOXY-5-O-(4-DEOXY-N-((3S)-HEXAHYDRO-2-OXO-1H-AZEPIN-3-YL)-.BETA.-L-ERYTHRO-HEX-4-ENOPYRANURONAMIDOSYL)-1-(3,4-DIHYDRO-2,4-DIOXO-1(2H)-PYRIMIDINYL)-3-O-METHYL-.ALPHA.-L-TALOFURANURONAMIDE
• NKM

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	0.8022	80.22%
Caco-2	-	0.8756	87.56%
Blood Brain Barrier	-	0.6250	62.50%
Human oral bioavailability	-	0.5714	57.14%
Subcellular localzation	Mitochondria	0.4921	49.21%
OATP2B1 inhibitior	-	0.7183	71.83%
OATP1B1 inhibitior	+	0.9047	90.47%
OATP1B3 inhibitior	+	0.9399	93.99%
MATE1 inhibitior	-	0.9800	98.00%
OCT2 inhibitior	-	0.8500	85.00%
BSEP inhibitior	-	0.9268	92.68%
P-glycoprotein inhibitior	-	0.4398	43.98%
P-glycoprotein substrate	+	0.7317	73.17%
CYP3A4 substrate	+	0.6747	67.47%
CYP2C9 substrate	-	0.5986	59.86%
CYP2D6 substrate	-	0.8619	86.19%
CYP3A4 inhibition	-	0.5203	52.03%
CYP2C9 inhibition	-	0.8074	80.74%
CYP2C19 inhibition	-	0.8212	82.12%
CYP2D6 inhibition	-	0.8451	84.51%
CYP1A2 inhibition	-	0.8500	85.00%
CYP2C8 inhibition	+	0.4500	45.00%
CYP inhibitory promiscuity	-	0.9132	91.32%
UGT catelyzed	+	0.6000	60.00%
Carcinogenicity (binary)	-	0.8700	87.00%
Carcinogenicity (trinary)	Non-required	0.5827	58.27%
Eye corrosion	-	0.9840	98.40%
Eye irritation	-	0.9405	94.05%
Skin irritation	-	0.7766	77.66%
Skin corrosion	-	0.9332	93.32%
Ames mutagenesis	-	0.6600	66.00%
Human Ether-a-go-go-Related Gene inhibition	-	0.5603	56.03%
Micronuclear	+	0.9600	96.00%
Hepatotoxicity	+	0.7104	71.04%
skin sensitisation	-	0.8673	86.73%
Respiratory toxicity	+	0.8333	83.33%
Reproductive toxicity	+	0.9556	95.56%
Mitochondrial toxicity	+	0.8875	88.75%
Nephrotoxicity	-	0.7917	79.17%
Acute Oral Toxicity (c)	III	0.6327	63.27%
Estrogen receptor binding	+	0.7286	72.86%
Androgen receptor binding	+	0.6777	67.77%
Thyroid receptor binding	-	0.5197	51.97%
Glucocorticoid receptor binding	+	0.6075	60.75%
Aromatase binding	+	0.6020	60.20%
PPAR gamma	+	0.6461	64.61%
Honey bee toxicity	-	0.7705	77.05%
Biodegradation	-	0.7500	75.00%
Crustacea aquatic toxicity	-	0.6600	66.00%
Fish aquatic toxicity	+	0.7803	78.03%

Targets

Proven Targets:

No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	99.31%	96.09%
CHEMBL4203	Q9HAZ1	Dual specificity protein kinase CLK4	97.17%	94.45%
CHEMBL204	P00734	Thrombin	94.60%	96.01%
CHEMBL2581	P07339	Cathepsin D	94.43%	98.95%
CHEMBL3137262	O60341	LSD1/CoREST complex	93.45%	97.09%
CHEMBL4040	P28482	MAP kinase ERK2	93.13%	83.82%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	92.75%	91.11%
CHEMBL3038477	P67870	Casein kinase II alpha/beta	92.32%	99.23%
CHEMBL5608	Q16288	NT-3 growth factor receptor	90.20%	95.89%
CHEMBL226	P30542	Adenosine A1 receptor	90.02%	95.93%
CHEMBL5469	Q14289	Protein tyrosine kinase 2 beta	88.25%	91.03%
CHEMBL4261	Q16665	Hypoxia-inducible factor 1 alpha	87.59%	85.14%
CHEMBL2635	P51452	Dual specificity protein phosphatase 3	86.71%	94.00%
CHEMBL3384	Q16512	Protein kinase N1	86.36%	80.71%
CHEMBL3437	Q16853	Amine oxidase, copper containing	84.48%	94.00%
CHEMBL1806	P11388	DNA topoisomerase II alpha	84.46%	89.00%
CHEMBL2094127	P06493	Cyclin-dependent kinase 1/cyclin B	83.75%	96.00%
CHEMBL2111367	P27986	PI3-kinase p110-alpha/p85-alpha	83.74%	94.33%
CHEMBL1907600	Q00535	Cyclin-dependent kinase 5/CDK5 activator 1	83.54%	93.03%
CHEMBL1907605	P24864	Cyclin-dependent kinase 2/cyclin E1	83.14%	92.88%
CHEMBL2492	P36544	Neuronal acetylcholine receptor protein alpha-7 subunit	83.08%	88.42%
CHEMBL4208	P20618	Proteasome component C5	82.35%	90.00%
CHEMBL3351	Q13085	Acetyl-CoA carboxylase 1	81.95%	93.04%
CHEMBL3830	Q2M2I8	Adaptor-associated kinase	81.73%	83.10%
CHEMBL3137261	O14744	PRMT5/MEP50 complex	81.58%	100.00%
CHEMBL2274	Q9H228	Sphingosine 1-phosphate receptor Edg-8	81.24%	100.00%
CHEMBL2535	P11166	Glucose transporter	81.02%	98.75%
CHEMBL1075317	P61964	WD repeat-containing protein 5	80.31%	96.33%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 5487121
• LOTUS: LTS0071318
• wikiData: Q76309600